The IMF is very pleased to see  research from Dr. Stephen Russell at the Mayo Clinic achieving success and starting to make a difference for patients. Dr. Russell presented the concept of this approach to International Myeloma Working Group (IMWG) members at our annual summit in London in 2011..

This is a very attractive new approach shifting from chemotherapy and novel therapies to a one-time decisive attack on the cancer, recruiting the body's immune system to do the cleanup job. The measles virus is just one of several being tested for this treatment strategy. This "virotherapy" must be individualized depending upon the patient's prior virus exposure.

In the current report on Dr. Russell's research, one patient has had dramatic benefit--which continues at the present time--the other patient, a temporary response. These patients had limited prior measles exposure. Dr. Russell is looking at other viruses which may be even more effective.

This initial 'proof of principle' is very encouraging. We must have patience--this type of research takes time and must be conducted very carefully to avoid/reduce safety concerns at each step, including safety studies in animals.

Congratulations to Dr. Russell for this initial success--we look forward to ongoing good news.


Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
New Studies Shed Light on Diet, Obesity in Myeloma and the Anti-Aging Power of Young Blood
Next Post
Measles Virotherapy: Will This Lead to a Cure?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.